2nd ANNUAL MIAMI THYROID ONCOLOGY SYMPOSIUM
February 2-3, 2018
Dear Colleagues,

We are delighted to host the second international Miami Thyroid Oncology Symposium with our outstanding faculty. Rapidly decoding the thyroid cancer genome and epigenome, we have entered into a new paradigm. A decade after the National Cancer Institute-initiated Cancer Genome Atlas project, a catalogue of genetic mutations associated with cancer has been created using genome sequencing and bioinformatics. The project has expanded to carry out the sequence analysis of thyroid cancer and its epigenomic characterization. The approach to clinical issues, thus, has moved beyond conventional diagnostics and therapeutic interventions. The risk stratification systems based on traditional parameters are challenged, and they may soon vacate their role for clear molecular markers. It is foreseeable that new and refined classification schemes based on genomics and their phenotypic expressions will be formulated. This approach should more accurately reflect the biologic differences between the different morphologic definitions we use today. We envision that the tumor differentiation/de-differentiation, and clinical behavior for each individual cancer will be defined by molecular markers, in addition to standard morpho-pathology. The technology is present, rapidly evolving and compelling. Empiricism in science of medicine and surgery has acquired a new method for testing the appropriate treatment for individual patients; that is molecular pathology, governed by genomics. The Miami Thyroid Oncology Symposium is a sophisticated forum for promotion of the science of thyroid cancer diagnosis and treatment in this new way of thinking.

The program is designed as an intense two-day symposium. The course on Radioactive Iodine (RAI) Theranostics will review the clinical indications and protocols of RAI imaging and treatment in the context of the new paradigm, and the course on the essentials of clinical genomics will provide a strong foundation for practicing physicians to help understand the evolving role of clinical molecular testing. The plenary session, in a didactic and interactive format, will review the clinical guidelines, address the controversies and bring fresh insight to the molecular and genomic theranostics. We welcome young investigators to present new research, ideas, and observations in poster format.

Lastly, we are indebted to our world-renown faculty for taking part in this exciting scientific symposium. We hope to fulfill our commitment in furthering the science of thyroid cancer towards the new frontiers.

Seza Gulce, MD, FACS
Symposium Co-Director

Yuri E. Nikiforov, MD, PhD
Symposium Co-Director
Symposium Faculty

• Seza Gulec, MD, FACS  
  Professor of Surgery and Nuclear Medicine,  
  Florida International University Herbert Wertheim College of Medicine  
  Chief of Surgery, Director of Thyroid Oncology Program Aventura Hospital and Medical Center  
  Symposium Co-Director

• Yuri Nikiforov, MD, PhD  
  Professor of Pathology  
  Vice-Chair for Molecular Pathology Department of Pathology, University of Pittsburgh  
  Symposium Co-Director

• Esma Akin, MD, FACP  
  Associate Professor of Radiology  
  Chief, Division of Nuclear Medicine, The George Washington University Medical Center

• James A. Fagin, MD  
  Professor of Medicine, Weill Cornell Medical College  
  Chief, Endocrinology Service, Memorial Sloan Kettering Cancer Center

• Bennett S. Greenspan, MD, MS  
  President, Society of Nuclear Medicine and Molecular Imaging

• Steven M. Larson, MD, FACNM, FACP  
  Professor, Radiology, Weill Cornell University Medical Center  
  Donna and Benjamin M. Rosen Chair  
  Attending Molecular Imaging and Therapy Service, Department of Radiology  
  Member and Lab Head, Molecular Pharmacology and Chemistry Program  
  Sloan Kettering Institute

• Bryan McIver, MD, PhD, FRCP(Edin)  
  Deputy Physician in Chief, Moffitt Cancer Center

• Marina N. Nikiforova, MD  
  Professor, Department of Pathology  
  Director, Molecular & Genomic Pathology Laboratory University of Pittsburgh Medical Center

• Sebastian Strom, MD  
  Chief Medical Officer, HCA South Atlantic Division

• Samantha Lazarovic, RN  
  Director of Physician and Provider Relations, AHMC  
  Symposium Coordinator
Day 1 - Pre-Symposium Course 1
Friday, February 2nd, 2018 - 7:30AM-12PM
RAI THERANOSTICS FOR PRACTICING CLINICIANS

Co-Directors: Seza Gulec, MD and Bennett Greenspan, MD

This course is designed to provide practical guidelines for the RAI treatment, addressing the current clinical controversies, but also emphasizing technical considerations. The rationale, methods and protocols of RAI imaging and therapy will be discussed both in post-operative ablation and metastatic disease settings in a systematic fashion. The theranostic role for evolving I-124 PET/CT imaging technology, and its integration into molecular diagnostics in the genomics paradigm will be stressed. The patient and disease risk stratification schemes and the value of dosimetric considerations in administered activity selection will be discussed with particular references to American Thyroid Association Guidelines. At the completion of the course, the attendees will receive a certificate of completion.

07:30-08:30 Breakfast & Opening Remarks - Bennett Greenspan
08:30-09:15 RAI Remnant Ablation - Seza Gulec
09:15-10:00 RAI Imaging and Therapy for Metastatic Disease - Esma Akin
10:00-10:45 I-124 PET/CT Imaging and Dosimetry - Seza Gulec
10:45-11:30 Clinical protocols for Thyroid Cancer Imaging and Therapy - Esma Akin
11:30-12:00 Therapeutic Profile of I-131 - Bennett Greenspan
12:00-13:00 Lunch

Day 1 - Pre-symposium Course 2
Friday, February 2nd, 2018 - 12PM-5PM
MOLECULAR BIOLOGY ESSENTIALS FOR PRACTICING CLINICIANS

Co-Directors: Marina Nikiforova, MD and Yuri Nikiforov, MD

This course will provide an overview of genetics of thyroid cancer and in-depth discussion of the ThyroSeq test. It will start with the review of basic principles of molecular biology pertinent to clinical practice. Next, the next generation sequencing (NGS) technology, its advantages and limitations, will be discussed. Detailed information on the ThyroSeq test will be provided including the new version of the test. Several clinical situations will be discussed with emphasis on the ThyroSeq report interpretation and implications for patient management. At the completion of the course, the attendees will receive a certificate of completion and a voucher for one free ThyroSeq v3 test.

12:00-13:00 Lunch & Opening Remarks - Yuri Nikiforov
13:00-1345 Central dogma of molecular biology: DNA, RNA, Protein - Marina Nikiforova
13:45-14:30 Genetic variations in cancer, clonality - Yuri Nikiforov
14:30-15:00 Discussion
15:00-15:45 Principles of next-generation sequencing - Marina Nikiforova
15:45-16-30 Clinical Practice: Understanding molecular diagnostic reports - Yuri Nikiforov
16:30-16:45 Discussion & Closing Remarks
Day 2 - Plenary Session
Saturday, February 3rd, 2018, 7:30AM-5PM
FRONTIERS IN THYROID ONCOLOGY
Chair: Sebastian Strom, MD

07:30-08:30 Breakfast
08:15-08:30 Opening Remarks - Sebastian Strom
08:30-09:15 Thyroid Cancer Oncogenesis - James Fagin
09:15-10:00 Molecular Pathology of Thyroid Cancer - Yuri Nikiforov
10:00-10:45 Next-generation Sequencing of Thyroid cancer - Marina Nikiforova
10:45-11:00 Discussion
11:00-11:45 ATA 2015 Guidelines: A Critical Appraisal - Bryan McIver
11:45-12:00 Discussion
12:00-13:00 Lunch
12:30-13:15 Case Presentations - Resident Physicians
13:15-14:00 Miami Thyroid Oncology Consortium Registry: Surgical Insights - Seza Gulec
14:00-14:30 Diagnostic and Prognostic Value of Thyroseq - Yuri Nikiforov
14:30-14:45 Discussion
14:45-15:30 Radioactive Iodine (RAI) Theranostics - Steven Larson
15:30-16:00 Targetted Therapies in Thyroid Cancer - James Fagin
16:00-16:30 Vision for Molecular Thyroid Oncology: A 2019 Foresight - Bryan McIver
16:30-16:45 Discussion
16:45-17:00 Closing Remarks - Sebastian Strom
17:00-19:00 Cocktail Reception

FRONTIERS IN THYROID ONCOLOGY, Saturday, February 3rd 2018, 7:30AM-5PM
Physicians and Scientists: $180  |  Nurses and Allied Healthcare Professionals: $90
HCA Medical staff, Guest Physicians, ThyCa Members, Residents, Medical Students: Special Discount*

RAI THERANOSTICS FOR PRACTICING CLINICIANS  and MOLECULAR BIOLOGY ESSENTIALS FOR PRACTICING CLINICIANS
Pre-symposium Courses, Friday, February 2nd 2018, 7:30AM-5PM
Physicians and Scientists: $90  |  Nurses and Allied Healthcare Professionals: $45
HCA Medical staff, Guest Physicians, ThyCa Members, Residents, Medical Students: Special Discount*

On-line Registration: www.AventuraHospital.com/ThyroidSymposium  |  Registration by phone: 305-682-6677

*Enter Promo Code at point of registration
CONFERENCES VENUE
Kovens Conference Center

3000 NE 151st Street
North Miami, FL 33181
(305) 919-5000

Kovens Conference Center is located on FIU's Biscayne Bay Campus in North Miami. The surrounding area offers an exciting array of lodging, dining, shopping, and leisure activities.

ACCOMMODATIONS
Diplomat Beach Resort

3555 S Ocean Drive
Hollywood, FL 33019
(954) 602-6000

Set on the beach and across the street from fishing charters, this upscale resort is 10 miles from the Seminole Hard Rock Casino Hollywood.

ACCOMMODATIONS
AC Hotel Miami Aventura

20805 Biscayne Boulevard
Aventura, FL 33180
(786) 590-5100

Off Route 1 close to shops and restaurants, this contemporary hotel is a mile from Gulfstream Park’s casino and horse racing complex, 3 miles from Golden Beach and 8 miles from Fort Lauderdale-Hollywood International Airport.

For conference room rate information, please visit www.AventuraHospital.com/ThyroidSymposium

Symposium Sponsors

Thyroseq®
Thyroid Genomic Classifier

Jubilant DraxImage

CBLPath
A Sonic Healthcare Company
Miami Thyroid Oncology Consortium

Miami Thyroid Oncology Consortium (MTOC) is an academic alliance, primarily including endocrinologists and surgical endocrinologists, formed with the common goal of assembling their intellectual resources to improve patient care through scientific collaboration and translational research. The membership to the consortium is open to all physicians involved/interested in the care of patients with thyroid disorders and cancer. Miami Thyroid Oncology Consortium has launched a project entitled Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer. The purpose of this registry is to collect uniform genomics-centered data on patients with nodular thyroid disease and thyroid cancer in a prospective fashion. Miami Thyroid Oncology Consortium Projects are supported by Aventura Hospital and Medical Center and Miami Cancer Research Center.

Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer

Miami Thyroid Oncology Consortium has instituted a registry to collect uniform genomics-centered data on patients with nodular thyroid disease and cancer in a prospective fashion. After initial clinical evaluation, patients with thyroid nodules undergo standard ultrasonographic evaluation and a needle biopsy of the thyroid (fine needle aspiration (FNA) or core biopsy), as clinically indicated. Biopsy samples are evaluated by cyto-pathologically. A molecular/genomic profiling is obtained using Thyroseq v2 test in collaboration with University of Pittsburgh Medical Center (UPMC). Surgical treatment is performed as per clinically determined indications. Standard surgical pathology is processed and reported at the Aventura Hospital and Medical Center. A molecular/genomic profiling is obtained using Thyroseq v2 on the surgical specimen. All patients undergoing thyroid nodule work-up eligible for enrollment. The registry collects patient demographic and clinical data, cytopathology reports, and surgical pathology reports and slides (if/when a review is required). The data collection and review are currently in progress. The MTOC is actively recruiting new investigators to participate the registry as well as other translational research projects.
Future Symposia

3rd Annual Miami Thyroid Oncology Symposium
February 1-2, 2019

4th Annual Miami Thyroid Oncology Symposium
February 7-8, 2020